FINWIRES · TerminalLIVE
FINWIRES

Starbucks Momentum Continues After Strong Q3 Results, RBC Says

By

Starbucks' (SBUX) is maintaining momentum after "fundamentally strong" fiscal Q3 results, though questions remain about how long that strength can persist, RBC Capital Markets said Thursday in a report.

Starbucks raised its full-year guidance on Wednesday after Q3 revenue and earnings topped expectations. The company is accelerating store remodels, with revamped locations showing transaction growth across formats and customer segments, the report said.

Operational metrics, including store ranking, service speed and food availability, showed improvement, and the rewards program is tracking ahead of internal expectations, RBC said.

Still, Starbucks faces potential for further North America store closures, and full-year guidance implies limited upside for Q4 EPS, the report said.

RBC raised its price target on Starbucks stock to $115 from $110 and maintained its sector-perform rating.

Price: $107.43, Change: $+3.29, Percent Change: +3.16%

Related Articles

Wire

Houlihan Lokey Fiscal Q1 Adjusted Earnings, Revenue Fall; Shares Drop After Hours

Houlihan Lokey (HLI) reported fiscal Q1 adjusted earnings late Wednesday of $1.35 per diluted share, down from $2.14 a year earlier.Analysts polled by FactSet expected $1.64.Revenue in the three months ended June 30 fell to $511 million from $605 million a year earlier.Analysts expected $602.4 million.Houlihan Lokey shares fell 6.6% in after-hours trading.

$HLI
Wire

Four Corners Property Trust Q2 AFFO, Revenue Rise

Four Corners Property Trust (FCPT) reported Q2 adjusted funds from operations late Wednesday of $0.45 per diluted share, up from $0.44 a year earlier.Analysts polled by FactSet expected $0.45.Revenue in the quarter ended June 30 rose to $78.4 million from $72.8 million a year earlier.Four analysts expected $79 million.The company's shares rose 2% in after-hours trading.

$FCPT
Wire

Corcept Therapeutics Q2 Earnings, Revenue Rise; Shares Jump After Hours

Corcept Therapeutics (CORT) reported Q2 earnings late Wednesday of $0.36 per diluted share, up from $0.29 a year earlier.Analysts polled by FactSet expected $0.02.Revenue for the three months ended June 30 rose to $256.1 million from $194.4 million a year earlier.Analysts expected $221.1 million.The company boosted full-year revenue guidance to $1.1 billion to $1.2 billion from the prior forecast of $950 million to $1.05 billion.Analysts project $999.5 million.Corcept shares jumped 18% in after-hours trading.

$CORT